clinical trial · NCT05308901
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
Providence Health & Services·phase2·terminated·n = 6
Melanoma, UvealPembrolizumabLenvatinib
brief summary
The purpose of this study is to evaluate the efficacy of lenvatinib and pembrolizumab to treat metastatic uveal melanoma.
started
Aug 2, 2022
primary completion
Dec 3, 2024
completion
Aug 11, 2025
last updated
Aug 12, 2026
detailed description
This is a phase II, single arm, single institution clinical trial. Adults (age≥18 years-old) with immune checkpoint inhibitor naïve metastatic uveal melanoma will be evaluated for eligibility. Eligible participants will be treated with the combination of Lenvatinib 20 mg daily + pembrolizumab 200 mg IV every 3 weeks for a maximum of 2 years.
official title
A Phase II Clinical Trial Evaluating The Combination Of Lenvatinib Plus Pembrolizumab In Patients With Treatment Naive Metastatic Uveal Melanoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol